Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359
This study compared antiretroviral activity among 6 “salvage” therapy regimens. The study was a prospective, randomized, 2 × 3 factorial, multicenter study of the AIDS Clinical Trials Group. The study enrolled 277 human immunodeficiency virus (HIV)—infected patients naive to nonnucleoside analogues who had taken indinavir >6 months. The patients had 2000–200,000 HIV RNA copies/mL. Patients received saquinavir with ritonavir or nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral response between baseline and week 16. At week 16, 30% (77/254) of patients had ⩾500 HIV RNA copies/mL. Virologic response did not differ significantly between pooled ritonavir and nelfinavir groups (28% vs. 33%; P = .50) or between pooled delavirdine and delavirdine/adefovir groups (40% vs. 33%; P = .42). Pooled delavirdine groups had a greater virologie response rate than did adefovir groups (40% vs. 18%; P = .002). Overall, one-third of patients who experienced virologie failure on an indinavir-containing regimen suppressed virus load levels while they were taking a new salvage regimen.